Citations

Clear

1820 citation(s) found for "Israel, E".

Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations
Møller, Pål , McCuaig, Jeanna , Eisen, Andrea , Bordeleau, Louise , Zakalik, Dana , Metcalfe, Kelly , Olopade, Olufunmilayo I. , Sun, Ping , Narod, Steven A. , Sweet, Kevin , Elser, Christine , Wiesner, Georgia L. , Poll, Aletta, Kim, Raymond H. , Armel, Susan T., Demsky, Rochelle, Serfas, Kim, Panchal, Seema, Cullinane, Carey A., Reilly, Robert E., Mercer, L J, Dungan, J.S., Lemire, Edmond G., Zovato, Stefania , Rastelli, Antonella, Olopade, Olufunmilayo I , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Kim, Raymond H , Kotsopoulos, Joanne , Gronwald, Jacek , Huzarski, Tomasz , Pal, Tuya , Singer, Christian F. , Karlan, Beth Y. , Aeilts, Amber M. , Eng, Charis , Foulkes, William D. , Tung, Nadine , Couch, Fergus J. , Fruscio, Robert , Neuhausen, Susan L. , Cybulski, Cezary , Lubiński, Jan , Armel, Susan, Steele, Linda, Saal, Howard M. , Rayson, Daniel , Mercer, Leanne, Cajal, Teresa Ramón y , Cohen, Stephanie A.

Mayo Clinic

JAMA Oncology | February 29, 2024 | Volume: 10 | Issue: 4 | Pages: 484

10.1001/jamaoncol.2023.6937 | PMID 38421677 Get It

ImportancePreventive bilateral salpingo-oophorectomy is offered to women at high risk of ovarian cancer who carry a pathogenic variant in BRCA1 or BRCA2; however, the association of oophorectomy with all-cause mortality has not been clearly defined.ObjectiveTo evaluate the association between bilateral oophorectomy and all-cause mortality among women with a BRCA1 or BRCA2 sequence variation.Design, Setting, and ParticipantsIn this international, longitudinal cohort study of women with BRCA sequence variations, information on bilateral oophorectomy was obtained via biennial questionnaire. Participants were women with a BRCA1 or BRCA2 sequence variation, no prior history of cancer, and at least 1 follow-up questionnaire completed. Women were followed up from age 35 to 75 years for incident cancers and deaths. Cox proportional hazards regression was used to estimate the hazard ratios (HRs) and 95% CIs for all-cause mortality associated with a bilateral oophorectomy (time dependent). Data analysis was performed from January 1 to June 1, 2023.ExposuresSelf-reported bilateral oophorectomy (with or without salpingectomy).Main Outcomes and MeasuresAll-cause mortality, breast cancer–specific mortality, and ovarian cancer–specific mortality.ResultsThere were 4332 women (mean age, 42.6 years) enrolled in the cohort, of whom 2932 (67.8%) chose to undergo a preventive oophorectomy at a mean (range) age of 45.4 (23.0-77.0) years. After a mean follow-up of 9.0 years, 851 women had developed cancer and 228 had died; 57 died of ovarian or fallopian tube cancer, 58 died of breast cancer, 16 died of peritoneal cancer, and 97 died of other causes. The age-adjusted HR for all-cause mortality associated with oophorectomy was 0.32 (95% CI, 0.24-0.42; P < .001). The age-adjusted HR was 0.28 (95% CI, 0.20-0.38; P < .001) and 0.43 (95% CI, 0.22-0.90; P = .03) for women with BRCA1 and BRCA2 sequence variations, respectively. For women with BRCA1 sequence variations, the estimated cumulative all-cause mortality to age 75 years for women who had an oophorectomy at age 35 years was 25%, compared to 62% for women who did not have an oophorectomy. For women with BRCA2 sequence variations, the estimated cumulative all-cause mortality to age 75 years was 14% for women who had an oophorectomy at age 35 years compared to 28% for women who did not have an oophorectomy.Conclusions and RelevanceIn this cohort study among women with a BRCA1 or BRCA2 sequence variation, oophorectomy was associated with a significant reduction in all-cause mortality.
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations
Møller, Pål , Eisen, Andrea , Peck, Larissa , Bordeleau, Louise , Zakalik, Dana , Stempa, Klaudia , Dungan, J.S., Cullinane, Carey A., Olopade, Olufunmilayo I. , Metcalfe, Kelly , Sun, Ping , Narod, Steven A. , Sweet, Kevin , Velsher, Lea, McCuaig, Jeanna , Panchal, Seema, Poll, Aletta, Lemire, Edmond G., Serfas, Kim, Costalas, Josephine Wagner, Blum, Joanne L. , Olopade, Olufunmilayo I , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Lubiński, Jan , Kotsopoulos, Joanne , Pal, Tuya , Karlan, Beth Y. , Aeilts, Amber M. , Eng, Charis , Foulkes, William D. , Tung, Nadine , Couch, Fergus J. , Fruscio, Robert , Cajal, Teresa Ramón y , Singer, Christian F. , Neuhausen, Susan L. , Cybulski, Cezary , Gronwald, Jacek , Huzarski, Tomasz , Senter, Leigha , Saal, Howard M. , Armel, Susan Randall , Reilly, Richard B. , Cohen, Stephanie A.

Mayo Clinic

JAMA Oncology | February 29, 2024 | Volume: 10 | Issue: 4 | Pages: 493

10.1001/jamaoncol.2023.6944 | PMID 38421676 Get It

Importance Magnetic resonance imaging (MRI) surveillance is offered to women with a pathogenic variant in the BRCA1 or BRCA2 gene who face a high lifetime risk of breast cancer. Surveillance with MRI is effective in downstaging breast cancers, but the association of MRI surveillance with mortality risk has not been well defined. Objective To compare breast cancer mortality rates in women with a BRCA1 or BRCA2 sequence variation who entered an MRI surveillance program with those who did not. Design, Setting, and Participants Women with a BRCA1 or BRCA2 sequence variation were identified from 59 participating centers in 11 countries. Participants completed a baseline questionnaire between 1995 and 2015 and a follow-up questionnaire every 2 years to document screening histories, incident cancers, and vital status. Women who had breast cancer, a screening MRI examination, or bilateral mastectomy prior to enrollment were excluded. Participants were followed up from age 30 years (or the date of the baseline questionnaire, whichever was later) until age 75 years, the last follow-up, or death from breast cancer. Data were analyzed from January 1 to July 31, 2023. Exposures Entrance into an MRI surveillance program. Main Outcomes and Measures Cox proportional hazards modeling was used to estimate the hazard ratios (HRs) and 95% CIs for breast cancer mortality associated with MRI surveillance compared with no MRI surveillance using a time-dependent analysis. Results A total of 2488 women (mean [range] age at study entry 41.2 [30-69] years), with a sequence variation in the BRCA1 (n = 2004) or BRCA2 (n = 484) genes were included in the analysis. Of these participants, 1756 (70.6%) had at least 1 screening MRI examination and 732 women (29.4%) did not. After a mean follow-up of 9.2 years, 344 women (13.8%) developed breast cancer and 35 women (1.4%) died of breast cancer. The age-adjusted HRs for breast cancer mortality associated with entering an MRI surveillance program were 0.20 (95% CI, 0.10-0.43; P < .001) for women with BRCA1 sequence variations and 0.87 (95% CI, 0.10-17.25; P = .93) for women with BRCA2 sequence variations. Conclusion and Relevance Results of this cohort study suggest that among women with a BRCA1 sequence variation, MRI surveillance was associated with a significant reduction in breast cancer mortality compared with no MRI surveillance. Further studies of women with BRCA2 sequence variations are needed to ascertain these women obtain the same benefits associated with MRI surveillance.
Fracture risk based on high-resolution peripheral quantitative computed tomography measures does not vary with age in older adults—the bone microarchitecture international consortium prospective cohort study
Szulc, Paweł , Hannan, Marian T. , Merle, Blandine , Boyd, Steven K. , Hanley, David A. , Lespessailles, Éric , Bouxsein, Mary , Hannan, Marian T , Lespessailles, Eric , Szulc, Pawel , Boyd, Steven K , Dufour, Alyssa B , Kiel, Douglas P. , Chapurlat, Roland D , Sornay‐Rendu, Elisabeth , Whittier, Danielle E. , Goltzman, David , Wong, Andy Kin On , Khosla, Sundeep , Ferrari, Serge , Biver, Emmanuel , Samelson, Elizabeth J

Mayo Clinic

Journal of Bone and Mineral Research | February 29, 2024 | Volume: 39 | Issue: 5 | Pages: 561-570

10.1093/jbmr/zjae033 | PMID 38477737 Get It

Abstract Fracture risk increases with lower areal bone mineral density (aBMD); however, aBMD-related estimate of risk may decrease with age. This may depend on technical limitations of 2-dimensional (2D) dual energy X-ray absorptiometry (DXA) which are reduced with 3D high-resolution peripheral quantitative computed tomography (HR-pQCT). Our aim was to examine whether the predictive utility of HR-pQCT measures with fracture varies with age. We analyzed associations of HR-pQCT measures at the distal radius and distal tibia with two outcomes: incident fractures and major osteoporotic fractures. We censored follow-up time at first fracture, death, last contact or 8 years after baseline. We estimated hazard ratios (HR) and 95%CI for the association between bone traits and fracture incidence across age quintiles. Among 6835 men and women (ages 40–96) with at least one valid baseline HR-pQCT scan who were followed prospectively for a median of 48.3 months, 681 sustained fractures. After adjustment for confounders, bone parameters at both the radius and tibia were associated with higher fracture risk. The estimated HRs for fracture did not vary significantly across age quintiles for any HR-pQCT parameter measured at either the radius or tibia. In this large cohort, the homogeneity of the associations between the HR-pQCT measures and fracture risk across age groups persisted for all fractures and for major osteoporotic fractures. The patterns were similar regardless of the HR-pQCT measure, the type of fracture, or the statistical models. The stability of the associations between HR-pQCT measures and fracture over a broad age range shows that bone deficits or low volumetric density remain major determinants of fracture risk regardless of age group. The lower risk for fractures across measures of aBMD in older adults in other studies may be related to factors which interfere with DXA but not with HR-pQCT measures.
Incidence and clinical outcomes of perforations during mechanical thrombectomy for medium vessel occlusion in acute ischemic stroke: A retrospective, multicenter, and multinational study
Musmar, Basel , Salim, Hamza , Kobeissi, Hassan , Shaikh, Hamza , Khalife, Jane , Abdalkader, Mohamad , Klein, Piers , Heit, Jeremy J. , Regenhardt, Robert W. , Cancelliere, Nicole M , Amllay, Abdelaziz , Dusart, Anne , Bellante, Flavio, Rouchaud, Aymeric , Puri, Ajit S , Dyzmann, Christian , Kan, Peter , Colasurdo, Marco , Berge, Jérôme , Barreau, Xavier , Nedelcu, Simona , Henninger, Nils , Marotta, Thomas R. , Stapleton, Christopher J. , Rabinov, James D. , Dofuku, Shogo , Tan, Benjamin Yong‐Qiang , Salazar‐Marioni, Sergio , Capirossi, Carolina , Chervak, Lina , Adeeb, Nimer , Tjoumakaris, Stavropoula , Khandelwal, Priyank , Biswas, Arundhati , Clarençon, Frédéric , Elhorany, Mahmoud , Premat, Kévin , Valente, Iacopo , Filipe, João Pedro , Varela, Ricardo , Quintero‐Consuegra, Miguel , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Yedavalli, Vivek , Aziz, Yasmin , Stracke, Christian Paul , Kadirvel, Ramanathan , Hsieh, Cheng‐Yang , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Musmar, Basel , Salim, Hamza , Kobeissi, Hassan , Klein, Piers , Nguyen, Thanh N , Regenhardt, Robert W , Bellante, Flavio , Forestier, Géraud , Marnat, Gaultier , Ota, Takahiro , Dofuku, Shogo , Yeo, Leonard Ll , Salazar-Marioni, Sergio , Jabbour, Pascal , Gonzalez, Nestor R , Möhlenbruch, Markus A , Jesser, Jessica , Aziz, Yasmin , Alexandru Radu, Răzvan , Faizy, Tobias D , Fahed, Robert , Liebeskind, David S. , Heit, Jeremy J , Yedavalli, Vivek S , Cancelliere, Nicole M , Rouchaud, Aymeric , Colasurdo, Marco , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Dmytriw, Adam A. , Ghozy, Sherief , Siegler, James E. , Nguyen, Thanh N. , Bernstock, Joshua D. , Naamani, Kareem El , Meyer, Lukas , Forestier, Géraud , Saleme, Suzana , Mounayer, Charbel , Fiehler, Jens , Kühn, Anna Luisa , Sibon, Igor , Gopinathan, Anil , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Renieri, Leonardo , Mowla, Ashkan , Vagal, Achala , Cuellar, Hugo , Jabbour, Pascal , Khandelwal, Priyank , Pedicelli, Alessandro , Schiphorst, Adrien ter , Harker, Pablo , Gory, Benjamin , Hecker, Constantin , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Thomas, Ajith J , Radu, Răzvan Alexandru , Fahed, Robert , Weyland, Charlotte S. , Mendes Pereira, Vitor

Mayo Clinic

European Stroke Journal | February 27, 2024 | Volume: 9 | Issue: 2 | Pages: 328-337

10.1177/23969873231219412 | PMID 38409796 Get It

Abstract Background: Mechanical thrombectomy (MT) has revolutionized the treatment of acute ischemic stroke (AIS) due to large vessel occlusion (LVO), but its efficacy and safety in medium vessel occlusion (MeVO) remain less explored. This multicenter, retrospective study aims to investigate the incidence and clinical outcomes of vessel perforations (confirmed by extravasation during an angiographic series) during MT for AIS caused by MeVO. Methods: Data were collected from 37 academic centers across North America, Asia, and Europe between September 2017 and July 2021. A total of 1373 AIS patients with MeVO underwent MT. Baseline characteristics, procedural details, and clinical outcomes were analyzed. Results: The incidence of vessel perforation was 4.8% (66/1373). Notably, our analysis indicates variations in perforation rates across different arterial segments: 8.9% in M3 segments, 4.3% in M2 segments, and 8.3% in A2 segments (p = 0.612). Patients with perforation had significantly worse outcomes, with lower rates of favorable angiographic outcomes (TICI 2c-3: 23% vs 58.9%, p < 0.001; TICI 2b-3: 56.5% vs 88.3%, p < 0.001). Functional outcomes were also worse in the perforation group (mRS 0–1 at 3 months: 22.7% vs 36.6%, p = 0.031; mRS 0–2 at 3 months: 28.8% vs 53.9%, p < 0.001). Mortality was higher in the perforation group (30.3% vs 16.8%, p = 0.008). Conclusion: This study reveals that while the occurrence of vessel perforation in MT for AIS due to MeVO is relatively rare, it is associated with poor functional outcomes and higher mortality. The findings highlight the need for increased caution and specialized training in performing MT for MeVO. Further prospective research is required for risk mitigation strategies.
Minimum clinical utility standards for wearable seizure detectors: A simulation study
Goldenholz, Daniel M. , Karoly, Philippa J. , Viana, Pedro F. , Nurse, Ewan S. , Bruno, Elisa , Richardson, Mark P. , Brinkmann, Benjamin H. , Westover, M. Brandon , Nurse, Ewan , Schulze-Bonhage, Andreas , Bruno, Elisa , Nasseri, Mona , Richardson, Mark P , Brinkmann, Benjamin H , Karoly, Phillipa J , Goldenholz, Daniel M , Viana, Pedro F , Westover, M Brandon , Loddenkemper, Tobias , Schulze‐Bonhage, Andreas , Vieluf, Solveig

Mayo Clinic

Epilepsia | February 17, 2024 | Volume: 65 | Issue: 4 | Pages: 1017-1028

10.1111/epi.17917 | PMID 38366862 Get It

AbstractObjectiveEpilepsy management employs self‐reported seizure diaries, despite evidence of seizure underreporting. Wearable and implantable seizure detection devices are now becoming more widely available. There are no clear guidelines about what levels of accuracy are sufficient. This study aimed to simulate clinical use cases and identify the necessary level of accuracy for each.MethodsUsing a realistic seizure simulator (CHOCOLATES), a ground truth was produced, which was then sampled to generate signals from simulated seizure detectors of various capabilities. Five use cases were evaluated: (1) randomized clinical trials (RCTs), (2) medication adjustment in clinic, (3) injury prevention, (4) sudden unexpected death in epilepsy (SUDEP) prevention, and (5) treatment of seizure clusters. We considered sensitivity (0%–100%), false alarm rate (FAR; 0–2/day), and device type (external wearable vs. implant) in each scenario.ResultsThe RCT case was efficient for a wide range of wearable parameters, though implantable devices were preferred. Lower accuracy wearables resulted in subtle changes in the distribution of patients enrolled in RCTs, and therefore higher sensitivity and lower FAR values were preferred. In the clinic case, a wide range of sensitivity, FAR, and device type yielded similar results. For injury prevention, SUDEP prevention, and seizure cluster treatment, each scenario required high sensitivity and yet was minimally influenced by FAR.SignificanceThe choice of use case is paramount in determining acceptable accuracy levels for a wearable seizure detection device. We offer simulation results for determining and verifying utility for specific use case and specific wearable parameters.
Phenoconversion in pure autonomic failure: a multicentre prospective longitudinal cohort study
Vernetti, Patricio Millar , Norcliffe‐Kaufmann, Lucy , Palma, Jose‐Alberto , Shibao, Cyndya A. , Goldstein, David S. , Low, Phillip A. , Miglis, Mitchell G. , Fanciulli, Alessandra , Millar Vernetti, Patricio , Goldstein, David S. , Singer, Wolfgang , Coon, Elizabeth Anne , Miglis, Mitchell G , Fanciulli, Alessandra , Kaufmann, Horacio , Palma, Jose-Alberto , Biaggioni, Italo , Shibao, Cyndya A , Peltier, Amanda , Freeman, Roy L. , Gibbons, Christopher H. , Coon, Elizabeth A. , Wenning, Gregor K. , Vernino, Steven , Betensky, Rebecca A.

Mayo Clinic

Brain | February 13, 2024 | Volume: 147 | Issue: 7 | Pages: 2440-2448

10.1093/brain/awae033 | PMID 38366572 Get It

Abstract We aimed to describe the clinical features of patients with pure autonomic failure (PAF) preceding phenoconversion that could be useful as predictive markers for advancing α-synuclein-associated neurodegeneration of the brain. Patients diagnosed with PAF were evaluated at eight centres (seven US-based and one European) and enrolled in a longitudinal observational cohort study (NCT01799915). Subjects underwent detailed assessments of motor, sleep, olfactory, cognitive and autonomic function and were followed prospectively to determine whether they developed parkinsonism or dementia for up to 10 years. We identified incident cases of Parkinson's disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA) and computed hazard ratios for phenoconversion as functions of clinical features. A total of 209 participants with PAF with a median disease duration of 6 years (IQR: 3–10) were enrolled. Of those, 149 provided follow-up information at an office or telemedicine visit. After a mean follow-up duration of 3 years, 48 (33%) participants phenoconverted (42% to PD, 35% to DLB and 23% to MSA). Faster phenoconversion from study enrolment to any diagnosis was associated with urinary and sexual dysfunction [hazard ratio (HR) 5.9, 95% confidence interval (CI): 1.6–22 and HR: 3.6, 95% CI: 1.1–12] followed by subtle motor signs (HR: 2.7, 95% CI: 1.2–6), trouble swallowing (HR 2.5, 95% CI: 1.4–4.5) and changes in speech (HR:2.4, 95% CI:1.1–4.8) at enrolment. Subjects reporting deterioration of handwriting were more likely to phenoconvert to PD (HR: 2.6, 95% CI: 1.1–5.9) and those reporting difficulty handling utensils were more likely to phenoconvert to DLB (HR: 6.8, 95% CI: 1.2–38). Patients with a younger age of PAF onset (HR: 11, 95% CI: 2.6–46), preserved olfaction (HR: 8.7, 95% CI: 1.7–45), anhidrosis (HR: 1.8, 95% CI: 1–3.1, P = 0.042) and severe urinary problems (HR 1.6, 95% CI: 1–2.5, P = 0.033) were more likely to phenoconvert to MSA. The best autonomic predictor of PD was a blunted heart rate increase during the tilt-table test (HR: 6.1, 95% CI: 1.4–26). Patients with PAF have an estimated 12% (95% CI: 9–15%) per year annual risk following study entry of phenoconverting to a manifest CNS synucleinopathy.
Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy
Hamnvik, Ole‐Petter R. , Davidge‐Pitts, Caroline , Ariel, Danit , Abramowitz, Jessica , Soe, Kyaw , Sarvaideo, Jenna , Kelley, Carly E. , Hamnvik, Ole-Petter R , Iwamoto, Sean J , Rothman, Micol Sara , Safer, Joshua D. , Tangpricha, Vin , Irwig, Michael S. , Iwamoto, Sean J.

Mayo Clinic

Transgender Health | February 12, 2024 | Volume: 9 | Issue: 6 | Pages: 463-465

10.1089/trgh.2023.0209 | PMID 39735380 Get It

Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5–30 mg every 2 weeks or 2–10 mg weekly with estradiol cypionate or valerate interchangeably. Data among transgender and gender-diverse patients are limited due to local unavailability and concerns around laboratory assay variability and estradiol (E2) level fluctuation. We note a concerning trend where patients are prescribed high-dose injections based on the guidelines leading to serum E2 levels well above the range recommended in the same guidelines. Our review indicates that 5 mg weekly or lower should be prescribed when initiating injectable estrogens to avoid supraphysiologic E2 levels.
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa
Peeva, Elena , Forman, Seth , Moiin, Ali, Khattri, Saakshi , Mangold, Aaron R. , Ghosh, Pranab , Banfield, Christopher , Mangold, A R , Kimball, Alexa B. , Porter, Martina Lee , Oemar, Barry S.

Mayo Clinic

NEJM Evidence | February 9, 2024 | Volume: 3 | Issue: 3 | Pages: No page available

10.1056/evidoa2300155 | PMID 38335032 Get It

External Validation of the 2023 Duke–International Society for Cardiovascular Infectious Diseases Diagnostic Criteria for Infective Endocarditis
Vaart, Thomas W. van der , Durack, David T., Karchmer, Adolf W. , Moreillon, Philippe, Selton‐Suty, Christine , Fowler, Vance G. , Meer, Jan T. M. van der, van der Vaart, Thomas W , Rasmussen, Magnus , Selton-Suty, Christine , Bossuyt, Patrick M. , Baddour, Larry M. , Bayer, Arnold S. , Durante‐Mangoni, Emanuele , Holland, Thomas L , Miró, José María , Fowler, Vance G.

Mayo Clinic

Clinical Infectious Diseases | February 8, 2024 | Volume: 78 | Issue: 4 | Pages: 922-929

10.1093/cid/ciae033 | PMID 38330166 Get It

Abstract Background The 2023 Duke–International Society of Cardiovascular Infectious Diseases (ISCVID) criteria for infective endocarditis (IE) were introduced to improve classification of IE for research and clinical purposes. External validation studies are required. Methods We studied consecutive patients with suspected IE referred to the IE team of Amsterdam University Medical Center (from October 2016 to March 2021). An international expert panel independently reviewed case summaries and assigned a final diagnosis of “IE” or “not IE,” which served as the reference standard, to which the “definite” Duke-ISCVID classifications were compared. We also evaluated accuracy when excluding cardiac surgical and pathologic data (“clinical” criteria). Finally, we compared the 2023 Duke-ISCVID with the 2000 modified Duke criteria and the 2015 and 2023 European Society of Cardiology (ESC) criteria. Results A total of 595 consecutive patients with suspected IE were included: 399 (67%) were adjudicated as having IE; 111 (19%) had prosthetic valve IE, and 48 (8%) had a cardiac implantable electronic device IE. The 2023 Duke-ISCVID criteria were more sensitive than either the modified Duke or 2015 ESC criteria (84.2% vs 74.9% and 80%, respectively; P < .001) without significant loss of specificity. The 2023 Duke-ISCVID criteria were similarly sensitive but more specific than the 2023 ESC criteria (94% vs 82%; P < .001). The same pattern was seen for the clinical criteria (excluding surgical/pathologic results). New modifications in the 2023 Duke-ISCVID criteria related to “major microbiological” and “imaging” criteria had the most impact. Conclusions The 2023 Duke-ISCVID criteria represent a significant advance in the diagnostic classification of patients with suspected IE.
Coexistence of Celiac Disease and Eosinophilic Gastroenteropathy
Rosenthal, Eldad, Bentur, Lea , Gleich, Gerald J. , Naveh, Yehezkel, Amirav, Israel

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 7, 2024 | Volume: 33 | Issue: 2 | Pages: 200-201

10.1002/j.1536-4801.2001.tb07437.x Get It